ADC‐159 was combined with anti‐PD‐L1, anti‐PD‐1 or anti‐CTLA‐4 antibodies and used to treat immune‐competent mice bearing CT‐26 allograft tumours. This evidence concerns the gene CTLA4 and neoplasm.